
Sarclisa Receives FDA Priority Review for Treating Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) for Priority Review. The application is for the investigational use of Sarclisa…












